v3.26.1
Condensed Statements of Changes in Shareholders’ Deficit (Unaudited) - USD ($)
Class A
Ordinary Shares
Class B
Ordinary Shares
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2025 $ 575 $ 24,425 $ (63,391) $ (38,391)
Balance (in Shares) at Dec. 31, 2025 5,750,000 [1]      
Issuance of Class B ordinary shares to independent directors $ 12 510 522
Issuance of Class B ordinary shares to independent directors (in Shares) 120,000 [1]      
Forfeiture of founder shares $ (12) 12
Forfeiture of founder shares (in Shares) (120,000) [1]      
Net Income (Loss) (40,043) (40,043)
Balance at Mar. 31, 2026 $ 575 24,947 (103,434) (77,912)
Balance (in Shares) at Mar. 31, 2026 5,750,000 [1]      
Balance at Dec. 31, 2025 $ 575 24,425 (63,391) (38,391)
Balance (in Shares) at Dec. 31, 2025 5,750,000 [1]      
Net Income (Loss)         1,579,393
Balance at Jun. 30, 2026 $ 24 $ 575 (11,069,436) (11,068,837)
Balance (in Shares) at Jun. 30, 2026 235,000 5,750,000 [1]      
Balance at Mar. 31, 2026 $ 575 24,947 (103,434) (77,912)
Balance (in Shares) at Mar. 31, 2026 5,750,000 [1]      
Accretion of Class A ordinary shares to redemption amount (4,813,617) (12,585,438) (17,399,055)
Sale of Private Placement Units $ 24 2,349,976 2,350,000
Sale of Private Placement Units (in Shares) 235,000 [1]      
Fair value of Public Warrants at issuance 2,606,667 2,606,667
Allocated value of transaction costs to Class A ordinary shares (167,973)   (167,973)
Net Income (Loss) 1,619,436 1,619,436
Balance at Jun. 30, 2026 $ 24 $ 575 $ (11,069,436) $ (11,068,837)
Balance (in Shares) at Jun. 30, 2026 235,000 5,750,000 [1]      
[1] This number includes an aggregate of up to 750,000 Class B ordinary shares subject to forfeiture by the Sponsor if the over-allotment option was not exercised in full or in part by the underwriter (Note 6). On March 30, 2026, the Company issued an aggregate of 120,000 founder shares to its three independent directors, with each director receiving 40,000 shares, at a purchase price of approximately $0.004 per share for an aggregate purchase price of $522. In connection with these issuances, the Sponsor surrendered to the Company, for no consideration, an equal number of founder shares. On April 15, 2026, the underwriter notified the Company of its intent to exercise its over-allotment option in full and on April 20, 2026, the underwriter purchased an additional 3,000,000 units. As such, the 750,000 Class B ordinary shares are no longer subject to forfeiture.